Literature DB >> 2118969

Recombinant IL-4 inhibits IL-6 synthesis by adherent peripheral blood cells in vitro.

R Gibbons1, O Martinez, M Matli, F Heinzel, M Bernstein, R Warren.   

Abstract

IL-4 has been shown to participate in interregulatory networks with other cytokines including IL-2, IFN-gamma, IL-1 beta, and TNF-alpha. The ability of recombinant IL-4 (rIL-4) to modulate the synthesis and release of IL-6 was investigated in vitro. LPS-stimulated adherent cells (AC) from human peripheral blood secreted IL-6 as determined by ELISA and bioassay with the B9 hybridoma cell line. The secretion of IL-6 peaked between 12-16 h after LPS stimulation. The addition of rIL-4 inhibited LPS-induced IL-6 production measured at 8 h. The inhibitory effect of rIL-4 on IL-6 secretion was dose-dependent and occurred at doses as low as 0.001 U/ml (0.01 pg/ml). Recombinant IL-4 was added to the cultures for various periods and removed by aspiration of the medium and washing the cells. The subsequent LPS-induction of IL-6 secretion was reduced in cultures exposed to rIL-4 for as little as 5 minutes indicating that the effect of rIL-4 on the monocytes was rapid and irreversible. Northern blot analysis revealed that the effect of rIL4 on LPS-induced production of IL-6 by AC occurred at least in part at the level of transcription. In contrast, PMA-induced IL-6 gene transcription was not affected by rIL-4. These findings indicate that rIL-4 can regulate the synthesis of IL-6 by adherent peripheral blood mononuclear cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2118969

Source DB:  PubMed          Journal:  Lymphokine Res        ISSN: 0277-6766


  8 in total

1.  Inhibition of interleukin-6 promoter activity by the 24 kDa isoform of fibroblast growth factor-2 in HeLa cells.

Authors:  I Delrieu; J C Faye; F Bayard; A Maret
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

2.  Interleukin-4 induces the synthesis and secretion of MCP-1/JE by human endothelial cells.

Authors:  B J Rollins; J S Pober
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

3.  Interleukin 4 suppresses the spontaneous growth of chronic myelomonocytic leukemia cells.

Authors:  K Akashi; T Shibuya; M Harada; Y Takamatsu; N Uike; T Eto; Y Niho
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

4.  Evidence that interleukin-4 suppression of lymphokine-activated killer cell induction is mediated through monocytes.

Authors:  B Brooks; H Parry; J Lawry; R Rees
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

Review 5.  Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation?

Authors:  W L Biffl; E E Moore; F A Moore; V M Peterson
Journal:  Ann Surg       Date:  1996-11       Impact factor: 12.969

6.  Growth factors controlling interleukin-4 action on hematopoietic progenitors.

Authors:  A Ferrajoli; T F Zipf; M Talpaz; E A Felix; Z Estrov
Journal:  Ann Hematol       Date:  1993-12       Impact factor: 3.673

7.  Serum IL-4, IL-10 and IL-6 levels in inflammatory arthritis.

Authors:  F M Cicuttini; K A Byron; D Maher; A M Wootton; K D Muirden; J A Hamilton
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

8.  Interleukin 7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes.

Authors:  M R Alderson; T W Tough; S F Ziegler; K H Grabstein
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.